RenovoRx
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2570 W El Camino Real Ste 320, Mountain ...Phone Number
(650) 284-4433Website
www.renovorx.comRevenue
<$5 MillionStock Symbol
RNXTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About RenovoRx
RenovoRx, Inc. (Nasdaq: RNXT) is a targeted oncology company focused on developing and commercializing innovative local drug-delivery therapies for cancer. The companys FDA-cleared RenovoCath® catheter and patented Trans-Arterial Micro-Perfusion (TAMP) platform are designed to deliver therapeutics directly through the arterial wall to bathe tumors at the disease site, with the goal of improving efficacy while reducing systemic toxicity compared to traditional IV therapies. RenovoRx aims to transform cancer care by enabling safer, more precise delivery of diagnostic and therapeutic agents to patients with high unmet medical needs.Explore more
RenovoRx Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RenovoRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when RenovoRx launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at RenovoRx
Click to see if RenovoRx had a recent Job posting/layoffs
Check if RenovoRx has recently received funding, and reach out quickly before it becomes old news!
RenovoRx, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once RenovoRx has new funding data
Earning: See what the market has to say on RenovoRx recently announced quarterly report
Check out if RenovoRx is spiking on competitors!
Recommended Actions
Find VP level buyers at RenovoRx
Find more new buyers
Compare Similar Companies to RenovoRx
Compare insights from companies similar to RenovoRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RenovoRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
RenovoRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about RenovoRx.
RenovoRx financials insights
Gather financial insights about RenovoRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$1.1M
2018
Unspecified
$10M
2024
Share Placement
$6.1M
2026
Private Equity
$10M
RenovoRx Tech Stack
A closer look at the technologies used by RenovoRx
See more technologies
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Project
Product Development, Medical Research, Healthcare Technology
RenovoRx News & Media
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, being held June 23-24, 2026.RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market ExclusivityRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side EffectsRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai and Chief Financial Officer Mark Voll will participate in the Alliance Global Partners (AGP) Annual Healthcare Company Showcase, hosted by Scott Henry, AGP’s Managing Director
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RenovoRx
Sign Up For FreeTo access detailed company insights
RenovoRx, Inc. (Nasdaq: RNXT) is a targeted oncology company focused on developing and commercializing innovative local drug-delivery therapies for cancer. The companys FDA-cleared RenovoCath® catheter and patented Trans-Arterial Micro-Perfusion (TAMP) platform are designed to deliver therapeutics directly through the arterial wall to bathe tumors... Read More
